Get started
Work

1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study

Year: 2024
Type: article
DOI: 10.1016/j.annonc.2024.08.1679
Authors: W.K. Kelly, L.J. Appleman, C-C. Lin, A.J. Armstrong, S.C. Fischer, D.W. Pook, J.L. Perez Gracia, J.L. Lee, D.R. Berthold, P.J. Ward, D.E. Castellano Gauna, L.G. Horvath, M. Kim, N. Matsubara, C. Sumey, M. Shabooti, Z. Yang, J. Connarn, J. Stieglmaier, D.C. Danila
Institutions: Thomas Jefferson University, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, National Taiwan University Hospital, Duke University, Duke Cancer Institute, Kantonsspital St. Gallen, Monash Medical Centre, Monash Health, Clinica Universidad de Navarra, Asan Medical Center, University of Ulsan, Centre Hospitalier Universitaire Vaudois, Oncology Hematology Care, Hospital Universitario 12 De Octubre, Chris O’Brien Lifehouse, Seoul National University Hospital, National Cancer Center Hospital East, Sanford Health, Amgen (United States), Amgen (Germany), Memorial Sloan Kettering Cancer Center
Language: English
Field: Medicine
Open Access status: bronze
Funder: Amgen
OpenAlex ID: W4402560265
FWCI: 1.161
Cites:
Cited by: 4
Related to: 10